Materials in the Na2O–CaO–SiO2–P2O5 System for Medical Applications
Abstract
:1. Introduction
2. Bioglass 45S5
2.1. The Na2O–CaO–SiO2–P2O5 System
- The red area (1) is the area of biological activity of class A, in which the corresponding biologically active glasses are osteoproductive (bind to bone and soft tissue, activate genes). The formation of the HAp layer is observed several hours after integration into a body.
- It was proved that bioglass grade 45S5 (Bioglass®) forms such a strong bond with a bone that the implant cannot be removed without destroying it [28]. This effect is observed due to the saturation of the bone tissue defect with calcium and silicon ions, which stimulate osteogenic cells to form a bone matrix;
- The green area (2) is the area of biological activity of class B, in which the corresponding biologically active glasses are osteoconductive (bind only to bone tissue). The formation of the HAp layer is observed from 24 to 96 h after integration into a body;
- The orange area (3) is the area of biological activity in which the formation of Cerabone bioglass ceramics takes place, consisting of apatite (Ca10(PO4)6(OH1F2)) and wollastonite (CaO·SiO2) crystals as well as a residual SiO2 glassy matrix [19]; however, unlike in other areas, the P2O5 content may vary;
- The purple area (4) is where the corresponding biologically active glasses are fully resorbed in the body after 10 to 30 days with a minimal restoration of damaged bone tissue;
- The gray area (5) is where the corresponding glasses do not form bonds even with bone and behave like a bioinert material;
- The white area (6) is where glass formation is not observed.
2.1.1. Benefits and Drawbacks of Bioactive Glass 45S5
2.1.2. Methods for Obtaining Crystal Phases
2.2. The Na2SiO3–CaSiO3 System
3. Calcium Phosphate/Bioglass 45S5 Composites
3.1. Hydroxyapatite/Bioglass 45S5 Composites
3.2. Tricalcium Phosphate/Bioglass 45S5 Composites
3.3. Calcium Phosphate with Ca/P = 1/Bioglass 45S5 Composites
3.3.1. Dicalcium Phosphates/Bioglass 45S5 Composites
3.3.2. Calcium Pyrophosphate/Bioglass 45S5 Composites
4. Other Ways to Obtain Composite Ceramics in the Na2O–CaO–SiO2–P2O5 System
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Zhou, X.; Zhang, N.; Mankoci, S.; Sahai, N. Silicates in orthopedics and bone tissue engineering materials. J. Biomed. Mater. Res. A 2017, 105, 2090–2102. [Google Scholar] [CrossRef] [PubMed]
- Boguszewska-Czubara, A.; Pasternak, K. Silicon in medicine and therapy. J. Elem. 2011, 16, 489–497. [Google Scholar] [CrossRef]
- Vapirov, V.V.; Feoktistov, V.M.; Venskovich, A.A.; Vapirova, N.V. On silicon’s behavior and its biological role in nature. Sci. Notes Petrozavodsk. State Univ. 2017, 2, 95–102. (In Russia) [Google Scholar]
- Henstock, J.R.; Canham, L.T.; Anderson, S.I. Silicon: The evolution of its use in biomaterials. Acta Biomater. 2015, 11, 17–26. [Google Scholar] [CrossRef]
- Carlisle, E.M. A relationship between silicon and calcium in bone formation. Fed. Proc. 1970, 29, 565. [Google Scholar]
- Carlisle, E.M. Silicon: An essential element for the chick. Science 1972, 178, 619–621. [Google Scholar] [CrossRef]
- Carlisle, E.M. Silicon: A requirement in bone formation independent of vitamin D1. Calcif. Tissue Int. 1981, 33, 27–34. [Google Scholar] [CrossRef]
- Reffitt, D.M.; Ogston, N.; Jugdaohsingh, R.; Cheung, H.F.J.; Evans, B.A.J.; Thompson, R.P.H.; Powell, J.J.; Hampson, G.N. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone 2003, 32, 127–135. [Google Scholar] [CrossRef]
- Keeting, P.E.; Oursler, M.J.; Wiegand, K.E.; Bonde, S.K.; Spelsberg, T.C.; Riggs, B.L. Zeolite a increases proliferation, differentiation, and transforming growth factor β production in normal adult human osteoblast-like cells in vitro. J. Bone Miner. Res. 1992, 7, 1281–1289. [Google Scholar] [CrossRef]
- Bose, S.; Tarafder, S.; Banerjee, S.S.; Davies, N.M.; Bandyopadhyay, A. Understanding in vivo response and mechanical property variation in MgO, SrO and SiO2 doped β-TCP. Bone 2011, 48, 1282–1290. [Google Scholar] [CrossRef]
- Midha, S.; van den Bergh, W.; Kim, T.B.; Lee, P.D.; Jones, J.R.; Mitchell, C.A. Bioactive glass foam scaffolds are remodelled by osteoclasts and support the formation of mineralized matrix and vascular networks in vitro. Adv. Heal. Mater. 2013, 2, 490–499. [Google Scholar] [CrossRef] [PubMed]
- Voronkov, M.G.; Zelchan, G.I.; Lukevits, E.Y. Silicon and Life: Biochemistry, Toxicology and Pharmacology of Silicon Compounds; Zinatne: Riga, Latvia, 1978. [Google Scholar]
- Sventskaya, N.V. Silicophosphate Biocomposite Materials with Adjustable Pore Structure for Osteoplastic Surgery. Ph.D. Thesis, Mendeleev University of Chemical Technology, Moscow, Russia, 2011. [Google Scholar]
- Hoppe, A.; Güldal, N.S.; Boccaccini, A.R. A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics. Biomaterials 2011, 32, 2757–2774. [Google Scholar] [CrossRef] [PubMed]
- Punj, S.; Singh, J.; Singh, K. Ceramic biomaterials: Properties, state of the art and future prospectives. Ceram. Int. 2021, 47, 28059–28074. [Google Scholar] [CrossRef]
- Kaimonov, M.; Safronova, T.; Shatalova, T.; Filippov, Y.; Tikhomirova, I.; Lukina, Y. Composite ceramics based on pastes including tricalcium phosphate and an aqueous solution of sodium silicate. J. Compos. Sci. 2022, 6, 267. [Google Scholar] [CrossRef]
- Hench, L.L. The story of bioglass®. J. Mater. Sci. Mater. Med. 2006, 17, 967–978. [Google Scholar] [CrossRef] [PubMed]
- Hench, L.L. Chronology of bioactive glass development and clinical applications. New J. Glass Ceram. 2013, 3, 67–73. [Google Scholar] [CrossRef]
- Hench, L.L. Bioceramics: From concept to clinic. J. Am. Ceram. Soc. 1991, 74, 1487–1510. [Google Scholar] [CrossRef]
- Demirkiran, H.; Hu, Y.; Zuin, L.; Appathurai, N.; Aswath, P.B. XANES Analysis of calcium and sodium phosphates and silicates and hydroxyapatite–bioglass®45S5 co-sintered bioceramics. Mater. Sci. Eng. C 2011, 31, 134–143. [Google Scholar] [CrossRef]
- Sujon, M.K.; Mohd Noor, S.N.F.; Zabidi, M.A.; Shariff, K.A. Combined sol–gel bioactive glass and β-tricalcium phosphate for potential dental tissue engineering: A preliminary study. J. Aust. Ceram. Soc. 2023, 59, 415–424. [Google Scholar] [CrossRef]
- Golubchikov, D.; Safronova, T.V.; Nemygina, E.; Shatalova, T.B.; Tikhomirova, I.N.; Roslyakov, I.V.; Khayrutdinova, D.; Platonov, V.; Boytsova, O.; Kaimonov, M.; et al. Powder synthesized from aqueous solution of calcium nitrate and mixed-anionic solution of orthophosphate and silicate anions for bioceramics production. Coatings 2023, 13, 374. [Google Scholar] [CrossRef]
- Sventskaya, N.V.; Lukina, Y.S.; Larionov, D.S.; Andreev, D.V.; Sivkov, S.P. 3D-matrix based on bioactive glass and calcium phosphates with controllable resorption rate for bone tissue replacement. Glass Ceram. 2017, 73, 342–347. [Google Scholar] [CrossRef]
- Fernandes, H.R.; Gaddam, A.; Rebelo, A.; Brazete, D.; Stan, G.E.; Ferreira José, M.F. Bioactive glasses and glass-ceramics for healthcare applications in bone regeneration and tissue engineering. Materials 2018, 11, 2530. [Google Scholar] [CrossRef] [PubMed]
- Zhou, P.; Xia, D.; Ni, Z.; Ou, T.; Wang, Y.; Zhang, H.; Mao, L.; Lin, K.; Xu, S.; Liu, J. Calcium silicate bioactive ceramics induce osteogenesis through oncostatin M. Bioact. Mater. 2021, 6, 810–822. [Google Scholar] [CrossRef]
- Ma, J.; Wang, C.Z.; Huang, B.X.; Zhao, X.C.; Chen, C.Z.; Yu, H.J. In vitro degradation and apatite formation of magnesium and zinc incorporated calcium silicate prepared by sol-gel method. Mater. Technol. 2021, 36, 420–429. [Google Scholar] [CrossRef]
- Karasu, B.; Yanar, A.O.; Koçak, A.; Kisacik, O. Bioactive glasses ceramic pigments view project bioactive glasses view project. El-Cezerî J. Sci. Eng. 2017, 4, 436–471. [Google Scholar]
- Venkatraman, S.K.; Swamiappan, S. Review on calcium- and magnesium-based silicates for bone tissue engineering applications. J. Biomed. Mater. Res. A 2020, 108, 1546–1562. [Google Scholar] [CrossRef]
- Kaur, G.; Kumar, V.; Pickrell, G.R.; Mauro, J.C.; Lin, Y.; Arya, S.K. Bioactive glasses in gene regulation and proliferation. In Biomedical, Therapeutic and Clinical Applications of Bioactive Glasses; Elsevier: Amsterdam, The Netherlands, 2019; pp. 175–200. [Google Scholar]
- Hench, L.L. Genetic design of bioactive glass. J. Eur. Ceram. Soc. 2009, 29, 1257–1265. [Google Scholar] [CrossRef]
- Ghosh, S.K.; Nandi, S.K.; Kundu, B.; Datta, S.; De, D.K.; Roy, S.K.; Basu, D. In vivo response of porous hydroxyapatite and β-tricalcium phosphate prepared by aqueous solution combustion method and comparison with bioglass scaffolds. J. Biomed. Mater. Res. B Appl. Biomater. 2008, 86, 217–227. [Google Scholar] [CrossRef]
- Lin, C.-C.; Leung, K.S.; Shen, P.; Chen, S.-F. Elasticity and structure of the compounds in the wollastonite (CaSiO3)–Na2SiO3 system: From amorphous to crystalline state. J. Mater. Sci. Mater. Med. 2015, 26, 39. [Google Scholar] [CrossRef]
- Hu, S.; Chang, J.; Liu, M.; Ning, C. Study on antibacterial effect of 45S5 bioglass®. J. Mater. Sci. Mater. Med. 2008, 20, 281–286. [Google Scholar] [CrossRef]
- Hu, S.; Ning, C.; Zhou, Y.; Chen, L.; Lin, K.; Chang, J. Antibacterial activity of silicate bioceramics. J. Wuhan. Univ. Technol. -Mater. Sci. Ed. 2011, 26, 226–230. [Google Scholar] [CrossRef]
- Sepulveda, P.; Jones, J.R.; Hench, L.L. In vitro dissolution of melt-derived 45S5 and sol-gel derived 58S bioactive glasses. J. Biomed. Mater. Res. 2002, 61, 301–311. [Google Scholar] [CrossRef] [PubMed]
- Vogel, M.; Voigt, C.; Gross, U.M.; Müller-Mai, C.M. In vivo comparison of bioactive glass particles in rabbits. Biomaterials 2001, 22, 357–362. [Google Scholar] [CrossRef] [PubMed]
- Kansal, I.; Reddy, A.; Muñoz, F.; Choi, S.J.; Kim, H.W.; Tulyaganov, D.U.; Ferreira, J.M.F. Structure, biodegradation behavior and cytotoxicity of alkali-containing alkaline-earth phosphosilicate glasses. Mater. Sci. Eng. C 2014, 44, 159–165. [Google Scholar] [CrossRef]
- Bellucci, D.; Sola, A.; Cannillo, V. A Revised Replication Method for Bioceramic Scaffolds. Bioceram. Dev. Appl. 2011, 1, D110401. [Google Scholar] [CrossRef]
- Aguilar-Reyes, E.A.; León-Patiño, C.A.; Jacinto-Diaz, B.; Lefebvre, L.-P. Structural characterization and mechanical evaluation of bioactive glass 45S5 foams obtained by a powder technology approach. J. Am. Ceram. Soc. 2012, 95, 3776–3780. [Google Scholar] [CrossRef]
- Vizureanu, P.; Bălțatu, M.S.; Sandu, A.V.; Achitei, D.C.; Nergis, D.D.B.; Perju, M.C. New trends in bioactive glasses for bone tissue: A review. In Current Concepts in Dental Implantology—From Science to Clinical Research; IntechOpen: London, UK, 2021; ISBN 978-1-83969-864-4. [Google Scholar]
- Haque, J.; Munna, A.H.; Ayon, A.S.R.; Shaitee, Z.R.; Saha, A. A comprehensive overview of the pertinence and possibilities of bioactive glass in the modern biological world. J. Biomater. 2020, 4, 23. [Google Scholar] [CrossRef]
- Menazea, A.A.; Abdelghany, A.M. Gamma irradiated Hench’s bioglass and their derivatives Hench’s bioglass-ceramic for bone bonding efficiency. Radiat. Phys. Chem. 2020, 174, 108932. [Google Scholar] [CrossRef]
- Sakka, S. Handbook of Sol-Gel Science and Technology: Processing, Characterization and Applications; Kluwer Academic Publishers: New York, NY, USA, 2005; Volume 2, ISBN 1-4020-7969-9. [Google Scholar]
- Jones, J.R. New trends in bioactive scaffolds: The importance of nanostructure. J. Eur. Ceram. Soc. 2009, 29, 1275–1281. [Google Scholar] [CrossRef]
- Jones, J.R. Review of bioactive glass: From hench to hybrids. Acta Biomater. 2013, 9, 4457–4486. [Google Scholar] [CrossRef]
- Lefebvre, L.; Chevalier, J.; Gremillard, L.; Zenati, R.; Thollet, G.; Bernache-Assolant, D.; Govin, A. Structural transformations of bioactive glass 45S5 with thermal treatments. Acta Mater. 2007, 55, 3305–3313. [Google Scholar] [CrossRef]
- Huang, L.C.; Lin, C.C.; Shen, P. Crystallization and stoichiometry of crystals in Na2CaSi2O6–P2O5 based bioactive glasses. Mater. Sci. Eng. A 2007, 452–453, 326–333. [Google Scholar] [CrossRef]
- Grasso, S.; Chinnam, R.K.; Porwal, H.; Boccaccini, A.R.; Reece, M.J. Low temperature spark plasma sintering of 45S5 bioglass®. J. Non Cryst. Solids 2013, 362, 25–29. [Google Scholar] [CrossRef]
- ICDD. PDF-4+ 2010 (Database); Kabekkodu, S., Ed.; International Centre for Diffraction Data: Newtown Square, PA, USA, 2010. [Google Scholar]
- Boccaccini, A.R.; Chen, Q.; Lefebvre, L.; Gremillard, L.; Chevalier, J. Sintering, crystallisation and biodegradation behaviour of bioglass®-derived glass–ceramics. Faraday Discuss. 2007, 136, 27. [Google Scholar] [CrossRef]
- Padmanabhan, S.K.; Gervaso, F.; Carrozzo, M.; Scalera, F.; Sannino, A.; Licciulli, A. Wollastonite/hydroxyapatite scaffolds with improved mechanical, bioactive and biodegradable properties for bone tissue engineering. Ceram. Int. 2013, 39, 619–627. [Google Scholar] [CrossRef]
- Huang, M.H.; Shen, Y.F.; Hsu, T.T.; Huang, T.H.; Shie, M.Y. Physical characteristics, antimicrobial and odontogenesis potentials of calcium silicate cement containing hinokitiol. Mater. Sci. Eng. C 2016, 65, 1–8. [Google Scholar] [CrossRef]
- Wu, C.; Chang, J. A review of bioactive silicate ceramics. Biomed. Mater. 2013, 8, 032001. [Google Scholar] [CrossRef]
- Kaur, G.; Kumar, V.; Baino, F.; Mauro, J.C.; Pickrell, G.; Evans, I.; Bretcanu, O. Mechanical properties of bioactive glasses, ceramics, glass-ceramics and composites: State-of-the-art review and future challenges. Mater. Sci. Eng. C 2019, 104, 109895. [Google Scholar] [CrossRef]
- Durgalakshmi, D.; Subhathirai, S.P.; Balakumar, S. Nano-bioglass: A versatile antidote for bone tissue engineering problems. Procedia Eng. 2014, 92, 2–8. [Google Scholar] [CrossRef]
- Lin, C.C.; Huang, L.C.; Shen, P. Na2CaSi2O6–P2O5 based bioactive glasses. Part 1: Elasticity and structure. J. Non Cryst. Solids 2005, 351, 3195–3203. [Google Scholar] [CrossRef]
- Du, R.; Chang, J. Preparation and characterization of bioactive sol-gel-derived Na2Ca2Si3O9. J. Mater. Sci. Mater. Med. 2004, 15, 1285–1289. [Google Scholar] [CrossRef] [PubMed]
- Xin, R.; Zhang, Q.; Gao, J. Identification of the wollastonite phase in sintered 45S5 bioglass and its effect on in vitro bioactivity. J. Non Cryst. Solids 2010, 356, 1180–1184. [Google Scholar] [CrossRef]
- Kantha, P.; Barnthip, N.; Pengpat, K.; Tunkasiri, T.; Pisitpipathsin, N. Influence of thermal treatment temperature on phase formation and bioactivity of glass-ceramics based on the SiO2-Na2O-CaO-P2O5 system. Key Eng. Mater. 2019, 798, 229–234. [Google Scholar] [CrossRef]
- Arstila, H.; Hupa, L.; Karlsson, K.H.; Hupa, M. Influence of heat treatment on crystallization of bioactive glasses. J. Non Cryst. Solids 2008, 354, 722–728. [Google Scholar] [CrossRef]
- Villicaña-Molina, E.; Aguilar-Reyes, E.A.; León-Patiño, C.A.; Nuñez-Anita, R.E. Preparation of CEL2 glass-ceramic porous scaffolds coated with chitosan microspheres that have a drug delivery function. Int. J. Appl. Ceram. Technol. 2019, 16, 1812–1822. [Google Scholar] [CrossRef]
- Fischer, R.X.; Tillmanns, E. Revised data for combeite, Na2Ca2Si3O9. Acta Crystallogr. C 1987, 43, 1852. [Google Scholar] [CrossRef]
- Ohsato, H.; Takéuchi, Y.; Maki, I. Structure of Na4Ca4Si6O18. Acta Crystallogr. C 1986, 42, 934–937. [Google Scholar] [CrossRef]
- Ohsato, H.; Maki, I.; Takeuchi, Y. Structure of Na2CaSi2O6. Acta Crystallogr. C Struct. Chem. 1985, 41, 1575–1577. [Google Scholar] [CrossRef]
- Safronova, T.V. Inorganic materials for regenerative medicine. Inorg. Mater. 2021, 57, 443–474. [Google Scholar] [CrossRef]
- Halim, N.A.A.; Hussein, M.Z.; Kandar, M.K. Nanomaterials-upconverted hydroxyapatite for bone tissue engineering and a platform for drug delivery. Int. J. Nanomed. 2021, 16, 6477–6496. [Google Scholar] [CrossRef] [PubMed]
- Mondal, S.; Dorozhkin, S.V.; Pal, U. Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite. WIREs Nanomed. Nanobiotechnol. 2018, 10, e1504. [Google Scholar] [CrossRef]
- Rizwan, M.; Hamdi, M.; Basirun, W.J. Bioglass® 45S5-based composites for bone tissue engineering and functional applications. J. Biomed. Mater. Res. A 2017, 105, 3197–3223. [Google Scholar] [CrossRef]
- Azarova, O.A.; Azarova, E.A.; Kharitonov, D.Y.; Podoprigora, A.V.; Shevchenko, L.V. Modern aspects of application of osteoplastic materials in dental surgery. Belgorod State Univ. Sci. Bull. Med. Pharm. Ser. 2019, 42, 215–223. [Google Scholar]
- Kanazawa, T. Inorganic Phosphate Materials; Elsevier: Amsterdam, The Netherlands, 1989. [Google Scholar]
- Xie, C.; Lu, X.; Wang, K.; Yuan, H.; Fang, L.; Zheng, X.; Chan, C.; Ren, F.; Zhao, C. Pulse electrochemical driven rapid layer-by-layer assembly of polydopamine and hydroxyapatite nanofilms via alternative redox in situ synthesis for bone regeneration. ACS Biomater. Sci. Eng. 2016, 2, 920–928. [Google Scholar] [CrossRef] [PubMed]
- Hidouri, M.; Dorozhkin, S.V.; Albeladi, N. Thermal behavior, sintering and mechanical characterization of multiple ion-substituted hydroxyapatite bioceramics. J. Inorg. Organomet. Polym. Mater. 2019, 29, 87–100. [Google Scholar] [CrossRef]
- Filip, D.G.; Surdu, V.-A.; Paduraru, A.V.; Andronescu, E. Current development in biomaterials—Hydroxyapatite and bioglass for applications in biomedical field: A review. J. Funct. Biomater. 2022, 13, 248. [Google Scholar] [CrossRef]
- Karacan, I.; Cox, N.; Dowd, A.; Vago, R.; Milthorpe, B.; Cazalbou, S.; Ben-Nissan, B. The synthesis of hydroxyapatite from artificially grown red sea hydrozoan coral for antimicrobacterial drug delivery system applications. J. Aust. Ceram. Soc. 2021, 57, 399–407. [Google Scholar] [CrossRef]
- Meng, Y.; Qiang, W.; Pang, J. Fabrication and microstructure of laminated HAP–45S5 bioglass ceramics by spark plasma sintering. Materials 2019, 12, 484. [Google Scholar] [CrossRef]
- Rizwan, M.; Hamdi, M.; Basirun, W.J.; Kondoh, K.; Umeda, J. Low pressure spark plasma sintered hydroxyapatite and bioglass® composite scaffolds for bone tissue repair. Ceram. Int. 2018, 44, 23052–23062. [Google Scholar] [CrossRef]
- Rizwan, M.; Genasan, K.; Murali, M.R.; Balaji Raghavendran, H.R.; Alias, R.; Cheok, Y.Y.; Wong, W.F.; Mansor, A.; Hamdi, M.; Basirun, W.J.; et al. In vitro evaluation of novel low-pressure spark plasma sintered HA–BG composite scaffolds for bone tissue engineering. RSC Adv. 2020, 10, 23813–23828. [Google Scholar] [CrossRef]
- Cozza, N.; Monte, F.; Bonani, W.; Aswath, P.; Motta, A.; Migliaresi, C. Bioactivity and mineralization of natural hydroxyapatite from cuttlefish bone and bioglass® co-sintered bioceramics. J. Tissue Eng. Regen. Med. 2018, 12, e1131–e1142. [Google Scholar] [CrossRef] [PubMed]
- Zarifah, N.A.; Matori, K.A.; Sidek, H.A.A.; Wahab, Z.A.; Salleh, M.A.M.; Zainuddin, N.; Khiri, M.Z.A.; Farhana, N.S.; Omar, N.A.S. Effect of hydroxyapatite reinforced with 45S5 glass on physical, structural and mechanical properties. Procedia Chem. 2016, 19, 30–37. [Google Scholar] [CrossRef]
- Bellucci, D.; Sola, A.; Gazzarri, M.; Chiellini, F.; Cannillo, V. A new hydroxyapatite-based biocomposite for bone replacement. Mater. Sci. Eng. C 2013, 33, 1091–1101. [Google Scholar] [CrossRef] [PubMed]
- Bellucci, D.; Cannillo, V.; Sola, A. A new highly bioactive composite for bone tissue repair. Int. J. Appl. Ceram. Technol. 2012, 9, 455–467. [Google Scholar] [CrossRef]
- Demirkiran, H.; Mohandas, A.; Dohi, M.; Fuentes, A.; Nguyen, K.; Aswath, P. Bioactivity and mineralization of hydroxyapatite with bioglass as sintering aid and bioceramics with Na3Ca6(PO4)5 and Ca5(PO4)2SiO4 in a silicate matrix. Mater. Sci. Eng. C 2010, 30, 263–272. [Google Scholar] [CrossRef] [PubMed]
- Goller, G.; Demirkiran, H.; Oktar, F.N.; Demirkesen, E. Processing and Characterization of Bioglass Reinforced Hydroxyapatite Composites. Ceram. Int. 2003, 29, 721–724. [Google Scholar] [CrossRef]
- Farnoush, H.; Muhaffel, F.; Cimenoglu, H. Fabrication and characterization of nano-HA-45S5 bioglass composite coatings on calcium-phosphate containing micro-arc oxidized CP-Ti substrates. Appl. Surf. Sci. 2015, 324, 765–774. [Google Scholar] [CrossRef]
- Ryu, J.H.; Kwon, J.S.; Kim, K.M.; Hong, H.J.; Koh, W.G.; Lee, J.; Lee, H.J.; Choi, H.J.; Yi, S.; Shin, H.; et al. Synergistic effect of porous hydroxyapatite scaffolds combined with bioactive glass/poly(lactic- co-glycolic acid) composite fibers promotes osteogenic activity and bioactivity. ACS Omega 2019, 4, 2302–2310. [Google Scholar] [CrossRef]
- Wang, D.G.; Chen, C.Z.; Ma, Q.S.; Jin, Q.P.; Li, H.C. A study on in vitro and in vivo bioactivity of HA/45S5 composite films by pulsed laser deposition. Appl. Surf. Sci. 2013, 270, 667–674. [Google Scholar] [CrossRef]
- Wang, D.G.; Chen, C.Z.; Yang, X.X.; Ming, X.C.; Zhang, W.L. Effect of bioglass addition on the properties of HA/BG composite films fabricated by pulsed laser deposition. Ceram. Int. 2018, 44, 14528–14533. [Google Scholar] [CrossRef]
- Tan, F.; Naciri, M.; Al-Rubeai, M. Osteoconductivity and growth factor production by MG63 osteoblastic cells on bioglass-coated orthopedic implants. Biotechnol. Bioeng. 2011, 108, 454–464. [Google Scholar] [CrossRef]
- Lukina, Y.; Safronova, T.; Smolentsev, D.; Toshev, O. Calcium phosphate cements as carriers of functional substances for the treatment of bone tissue. Materials 2023, 16, 4017. [Google Scholar] [CrossRef]
- Yu, L.; Li, Y.; Zhao, K.; Tang, Y.; Cheng, Z.; Chen, J.; Zang, Y.; Wu, J.; Kong, L.; Liu, S.; et al. A novel injectable calcium phosphate cement-bioactive glass composite for bone regeneration. PLoS ONE 2013, 8, e62570. [Google Scholar] [CrossRef]
- Stulajterova, R.; Medvecky, L.; Giretova, M.; Sopcak, T.; Kovalcikova, A. Effect of bioglass 45S5 addition on properties, microstructure and cellular response of tetracalcium phosphate/monetite cements. Mater. Charact. 2017, 126, 104–115. [Google Scholar] [CrossRef]
- Shuai, C.; Li, P.; Liu, J.; Peng, S. Optimization of TCP/HAP ratio for better properties of calcium phosphate scaffold via selective laser sintering. Mater. Charact. 2013, 77, 23–31. [Google Scholar] [CrossRef]
- Tarafder, S.; Bose, S. Polycaprolactone-coated 3D printed tricalcium phosphate scaffolds for bone tissue engineering: In vitro alendronate release behavior and local delivery effect on in vivo osteogenesis. ACS Appl. Mater. Interfaces 2014, 6, 9955–9965. [Google Scholar] [CrossRef] [PubMed]
- Safronova, T.V.; Selezneva, I.I.; Tikhonova, S.A.; Kiselev, A.S.; Davydova, G.A.; Shatalova, T.B.; Larionov, D.S.; Rau, J.V. Biocompatibility of biphasic α,β-tricalcium phosphate ceramics in vitro. Bioact. Mater. 2020, 5, 423–427. [Google Scholar] [CrossRef] [PubMed]
- Baino, F.; Caddeo, S.; Vitale-Brovarone, C. Sintering effects of bioactive glass incorporation in tricalcium phosphate scaffolds. Mater. Lett. 2020, 274, 128010. [Google Scholar] [CrossRef]
- He, F.; Qian, G.; Ren, W.; Li, J.; Fan, P.; Shi, H.; Shi, X.; Deng, X.; Wu, S.; Ye, J. Fabrication of β-tricalcium phosphate composite ceramic sphere-based scaffolds with hierarchical pore structure for bone regeneration. Biofabrication 2017, 9, 025005. [Google Scholar] [CrossRef]
- Gonzálvez-García, M.; Martinez, C.; Villanueva, V.; García-Hernández, A.; Blanquer, M.; Meseguer-Olmo, L.; Oñate Sánchez, R.; Moraleda, J.; Rodríguez-Lozano, F. Preclinical studies of the biosafety and efficacy of human bone marrow mesenchymal stem cells pre-seeded into β-TCP scaffolds after transplantation. Materials 2018, 11, 1349. [Google Scholar] [CrossRef]
- Marques, A.; Miranda, G.; Silva, F.; Pinto, P.; Carvalho, Ó. Review on current limits and potentialities of technologies for biomedical ceramic scaffolds production. J. Biomed. Mater. Res. B Appl. Biomater. 2021, 109, 377–393. [Google Scholar] [CrossRef] [PubMed]
- Bellucci, D.; Sola, A.; Cannillo, V. Hydroxyapatite and tricalcium phosphate composites with bioactive glass as second phase: State of the art and current applications. J. Biomed. Mater. Res. A 2016, 104, 1030–1056. [Google Scholar] [CrossRef] [PubMed]
- Chitra, S.; Bargavi, P.; Durgalakshmi, D.; Rajashree, P.; Balakumar, S. On the investigation of structural and biological properties of 45S5 bioglass and β-tricalcium phosphate nanostructured materials. In Proceedings of the Dae Solid State Physics Symposium 2018, Hisar, India, 18–22 December 2018; p. 030242. [Google Scholar] [CrossRef]
- Monfared, M.H.; Ranjbar, F.E.; Torbati, M.; Poursamar, S.A.; Lotfibakhshaiesh, N.; Ai, J.; Ebrahimi-Barough, S.; Azami, M. Preparation and characterization of 3D nanocomposite scaffold from bioactive glass/β-tricalcium phosphate via robocasting method for bone tissue engineering. J. Non Cryst. Solids 2022, 593, 121769. [Google Scholar] [CrossRef]
- Galván-Chacón, V.P.; Eqtesadi, S.; Pajares, A.; Miranda, P.; Guiberteau, F. Elucidating the role of 45S5 bioglass content in the density and flexural strength of robocast β-TCP/45S5 composites. Ceram. Int. 2018, 44, 12717–12722. [Google Scholar] [CrossRef]
- Westhauser, F.; Karadjian, M.; Essers, C.; Senger, A.-S.; Hagmann, S.; Schmidmaier, G.; Moghaddam, A. Osteogenic differentiation of mesenchymal stem cells is enhanced in a 45S5-supplemented β-TCP composite scaffold: An in-vitro comparison of vitoss and vitoss BA. PLoS ONE 2019, 14, e0212799. [Google Scholar] [CrossRef]
- Spirandeli, B.R.; Ribas, R.G.; Amaral, S.S.; Martins, E.F.; Esposito, E.; Vasconcellos, L.M.R.; Campos, T.M.B.; Thim, G.P.; Trichês, E.S. Incorporation of 45S5 bioglass via sol-gel in β-TCP scaffolds: Bioactivity and antimicrobial activity evaluation. Mater. Sci. Eng. C 2021, 131, 112453. [Google Scholar] [CrossRef]
- Lopes, J.H.; Magalhães, J.A.; Gouveia, R.F.; Bertran, C.A.; Motisuke, M.; Camargo, S.E.A.; de Sousa Trichês, E. Hierarchical structures of β-TCP/45S5 bioglass hybrid scaffolds prepared by gelcasting. J. Mech. Behav. Biomed. Mater. 2016, 62, 10–23. [Google Scholar] [CrossRef]
- Bose, S.; Bhattacharjee, A.; Banerjee, D.; Boccaccini, A.R.; Bandyopadhyay, A. Influence of random and designed porosities on 3D printed tricalcium phosphate-bioactive glass scaffolds. Addit. Manuf. 2021, 40, 101895. [Google Scholar] [CrossRef]
- Bergmann, C.; Lindner, M.; Zhang, W.; Koczur, K.; Kirsten, A.; Telle, R.; Fischer, H. 3D printing of bone substitute implants using calcium phosphate and bioactive glasses. J. Eur. Ceram. Soc. 2010, 30, 2563–2567. [Google Scholar] [CrossRef]
- Schickle, K.; Zurlinden, K.; Bergmann, C.; Lindner, M.; Kirsten, A.; Laub, M.; Telle, R.; Jennissen, H.; Fischer, H. Synthesis of novel tricalcium phosphate-bioactive glass composite and functionalization with RhBMP-2. J. Mater. Sci. Mater. Med. 2011, 22, 763–771. [Google Scholar] [CrossRef]
- Feng, P.; Deng, Y.; Duan, S.; Gao, C.; Shuai, C.; Peng, S. Liquid phase sintered ceramic bone scaffolds by combined laser and furnace. Int. J. Mol. Sci. 2014, 15, 14574–14590. [Google Scholar] [CrossRef] [PubMed]
- Hua, S.-B.; Su, J.; Deng, Z.-L.; Wu, J.-M.; Cheng, L.-J.; Yuan, X.; Chen, F.; Zhu, H.; Qi, D.-H.; Xiao, J.; et al. Microstructures and properties of 45S5 bioglass® & BCP bioceramic scaffolds fabricated by digital light processing. Addit. Manuf. 2021, 45, 102074. [Google Scholar] [CrossRef]
- Bohner, M. Resorbable biomaterials as bone graft substitutes. Mater. Today 2010, 13, 24–30. [Google Scholar] [CrossRef]
- Hasan, M.L.; Kim, B.; Padalhin, A.R.; Faruq, O.; Sultana, T.; Lee, B.T. In vitro and in vivo evaluation of bioglass microspheres incorporated brushite cement for bone regeneration. Mater. Sci. Eng. C 2019, 103, 109775. [Google Scholar] [CrossRef]
- Lukina, Y.S.; Sventskaya, N.V.; Golikova, P.V.; Sivkov, S.P.; Beletskii, B.I.; Zaitsev, V.V. Reaction-bonded bioresorbable composite material. Glass Ceram. 2013, 70, 195–199. [Google Scholar] [CrossRef]
- Cheah, C.W.; Al-Namnam, N.M.; Lau, M.N.; Lim, G.S.; Raman, R.; Fairbairn, P.; Ngeow, W.C. Synthetic material for bone, periodontal, and dental tissue regeneration: Where are we now, and where are we heading next? Materials 2021, 14, 6123. [Google Scholar] [CrossRef]
- Mirtchi, A.A.; Lemaitre, J.; Terao, N. Calcium phosphate cements: Study of the β-tricalcium phosphate—Monocalcium phosphate system. Biomaterials 1989, 10, 475–480. [Google Scholar] [CrossRef]
- Sheikh, Z.; Abdallah, M.-N.; Hanafi, A.; Misbahuddin, S.; Rashid, H.; Glogauer, M. Mechanisms of in vivo degradation and resorption of calcium phosphate based biomaterials. Materials 2015, 8, 7913–7925. [Google Scholar] [CrossRef]
- Lukina, Y.S.; Sventskaya, N.V. Biocomposite material based on dicalcium phosphate dihydrate. Glass Ceram. 2011, 67, 354–357. [Google Scholar] [CrossRef]
- Mabroum, H.; Noukrati, H.; Ben Youcef, H.; Lefeuvre, B.; Oudadesse, H.; Barroug, A. Physicochemical, setting, rheological, and mechanical properties of a novel bio-composite based on apatite cement, bioactive glass, and alginate hydrogel. Ceram. Int. 2021, 47, 23973–23983. [Google Scholar] [CrossRef]
- Renno, A.C.M.; van de Watering, F.C.J.; Nejadnik, M.R.; Crovace, M.C.; Zanotto, E.D.; Wolke, J.G.C.; Jansen, J.A.; van den Beucken, J.J.J.P. Incorporation of bioactive glass in calcium phosphate cement: An evaluation. Acta Biomater. 2013, 9, 5728–5739. [Google Scholar] [CrossRef] [PubMed]
- Safronova, T.; Kiselev, A.; Selezneva, I.; Shatalova, T.; Lukina, Y.; Filippov, Y.; Toshev, O.; Tikhonova, S.; Antonova, O.; Knotko, A. Bioceramics based on β-calcium pyrophosphate. Materials 2022, 15, 3105. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.Y.; Yang, D.A.; Zhao, H. Degradation behavior of β-Ca3 (PO4)2/β-Ca2P2O7 bioceramics. Key Eng. Mater. 2007, 336–338, 1650–1653. [Google Scholar] [CrossRef]
- Safronova, T.; Putlayev, V.; Bessonov, K.; Ivanov, V. Ceramics based on calcium pyrophosphate nanopowders. Process. Appl. Ceram. 2013, 7, 9–14. [Google Scholar] [CrossRef]
- Safronova, T.V.; Kurbatova, S.A.; Shatalova, T.B.; Knotko, A.V.; Yevdokimov, P.V.; Putlyayev, V.I. Calcium pyrophosphate powder for production of bioceramics synthesized from pyrophosphoric acid and calcium acetate. Inorg. Mater. Appl. Res. 2017, 8, 118–125. [Google Scholar] [CrossRef]
- Safronova, T.V.; Putlyaev, V.I.; Knot’ko, A.V.; Krut’ko, V.K.; Musskaya, O.N.; Ulasevich, S.A.; Vorob’eva, N.A.; Telitsin, V.D. Calcium phosphate ceramic in the system Ca(PO3)2–Ca2P2O7 based on powder mixtures containing calcium hydrophosphate. Glass Ceram. 2018, 75, 279–286. [Google Scholar] [CrossRef]
- Safronova, T.V.; Sadilov, I.S.; Chaikun, K.V.; Shatalova, T.B.; Filippov, Y.Y. Synthesis of monetite from calcium hydroxyapatite and monocalcium phosphate monohydrate under mechanical activation conditions. Russ. J. Inorg. Chem. 2019, 64, 1088–1094. [Google Scholar] [CrossRef]
- Safronova, T.V.; Shatalova, T.B.; Tikhonova, S.A.; Filippov, Y.Y.; Krut’ko, V.K.; Musskaya, O.N.; Kononenko, N.E. Synthesis of calcium pyrophosphate powders from phosphoric acid and calcium carbonate. Inorg. Mater. Appl. Res. 2021, 12, 986–992. [Google Scholar] [CrossRef]
- Filippov, Y.Y.; Orlov, E.D.; Klimashina, E.S.; Evdokimov, P.V.; Safronova, T.V.; Putlayev, V.I.; Rau, J.V. Colloidal forming of macroporous calcium pyrophosphate bioceramics in 3D-printed molds. Bioact. Mater. 2020, 5, 309–317. [Google Scholar] [CrossRef]
- Safronova, T.V.; Putlyaev, V.I. Powder systems for calcium phosphate ceramics. Inorg. Mater. 2017, 53, 17–26. [Google Scholar] [CrossRef]
- Bolarinwa, A.; Gbureck, U.; Purnell, P.; Bold, M.; Grover, L.M. Cement casting of calcium pyrophosphate based bioceramics. Adv. Appl. Ceram. 2010, 109, 291–295. [Google Scholar] [CrossRef]
- Kaimonov, M.R.; Safronova, T.V.; Filippov, Y.Y.; Shatalova, T.B.; Preobrazhenskii, I.I. Calcium phosphate powder for obtaining of composite bioceramics. Inorg. Mater. Appl. Res. 2021, 12, 34–39. [Google Scholar] [CrossRef]
- Ribas, R.G.; Schatkoski, V.M.; do Amaral Montanheiro, T.L.; de Menezes, B.R.C.; Stegemann, C.; Leite, D.M.G.; Thim, G.P. Current advances in bone tissue engineering concerning ceramic and bioglass scaffolds: A review. Ceram. Int. 2019, 45, 21051–21061. [Google Scholar] [CrossRef]
- Kaimonov, M.; Safronova, T.; Shatalova, T.; Filippov, Y.; Tikhomirova, I.; Sergeev, N. Composite ceramics in the Na2O–CaO–SiO2–P2O5 system obtained from pastes including hydroxyapatite and an aqueous solution of sodium silicate. Ceramics 2022, 5, 550–561. [Google Scholar] [CrossRef]
Melt–Quench [38,39,40,41,42] | Sol–Gel [43,44,45] | |
---|---|---|
Initial reagents | Sodium carbonate (Na2CO3); calcium carbonate (CaCO3) or calcium oxide (CaO); phosphorus pentoxide (P2O5); silicon dioxide (SiO2). | Tetraethylorthosilicate (TEOS) or tetramethylortosilicate (TMOS); triethyl phosphate (TEP); calcium nitrate tetrahydrate (Ca(NO3)2·4H2O); sodium nitrate (NaNO3). |
Steps |
|
|
Advantages | Traditional approach; simple. | Higher purity and homogeneity; a wide range of compositions; possibility of obtaining silica gel at room temperature. |
Disadvantages | Energy intensive; requires complete homogenization of the melt; may lead to contamination from the chemical substances; no possibility to fabricate porous scaffolds. | Dependence on pH; monoliths of bioactive glass (d > 1 cm) have cracks due to the shrinkage that occurs during drying and the evaporation of the liquid by-products of the condensation reaction; alkoxides are not suitable for large-scale production. |
Composition | Parameters of Sintering/Coating/ Cementation | Brief Characteristics of Materials | Evaluation of the Biocompatibility/ Bioactivity of Materials | Ref. | |
---|---|---|---|---|---|
Composites | |||||
Spark Plasma Sintering | HAp/45S5 laminated structure (m(HAp)/m(45S5) = 2/1) | T = 1223 K, P = 40 MPa, t = 16 min | Sintering of 45S5 with HAp and counter-diffusion of Ca and Na ions were observed at the phase interface. Large HAp grains (2 μm) were formed in the diffusion area. Crystallization of the 45S5 did not occur. The strain and stress of HAp/45S5 ceramics were both increased by 19 times (5.9%) and 1.89 times (79.8 MPa) compared with HAp ceramics (0.31% and 42.2 MPa). | No measurements were taken | [75] |
(100 − x)HAp/x45S5, x = 0, 2.5, 5, 10, 15, 20, 25, 30 wt.% [76] (100 − x)HAp/x45S5, x = 0, 10, 20, 30 wt.% [77] | T = 1000 °C, P = 3.67 MPa, t = 30 min | The crystalline phases were absent from the chemical reactions between the constituents or from the devitrification of glass. HAp without 45S5 transformed to β-tricalcium phosphate (β-TCP). Crystallization of the 45S5 did not occur. The greater the amount of 45S5, the more the transformation of HAp to β-TCP decreased due to the stabilization of HAp by 45S5. | SBF (14 days of immersion) test showed apatite layer formation for all composites. Composites showed an inhibition property against all the Staphylococcus spp. compared with HAp. The hBMSCs were able to attach, spread, and proliferate safely without toxic interference from the scaffolds, especially on HAp/45S5 (x = 30 wt.%). The mineralization activity of the hBMSCs increased with an increase in 45S5 concentration. Enhanced BMP-2, COL-1 secretion, and the osterix intracellular expression were observed in the hBMSCs seeded on HAp/45S5 (x = 30 wt.%). Composites exhibited resistance to monocyte migration. | [76,77] | |
Pressureless sintering | (100 − x)CF/x45S5 (CF—cuttlefish bone powder), (100 − x)HAp/x45S5, x = 30 wt.% | T = 900 °C, heating rate = 10 °C/min, cooled rate = 10 °C/min, t = 3 h | The CF/45S5 composite after sintering included HAp, Na3Ca6(PO4)5, and β-TCP. There was no evidence of any crystalline silicate phases. Silicon in amorphous form was localized in Ca-deficient areas of the surface. The HAp/45S5 composite after sintering included HAp and Na2Ca2Si2O7. Both strain and stress of CF/45S5 and HAp/45S5 composites were increased compared with HAp ceramics. | Incubation in DMEM for 7 days showed apatite layer formation for all composites. The MG-63 cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds, especially on CF/45S5 composites. The CF/45S5 composite was more effective at promoting ALP production compared to HAp/45S5 (the composite showed up-regulation of ALP activity as early as 3 days after the seeding). | [78] |
(100 − x)HAp/x45S5, x = 0, 20, 40, 60, 80 wt.% | T = 800 °C, t = 3 h | The HAp/45S5 (x = 20, 40 wt.%) composites after sintering included HAp, Ca5(PO4)2SiO4, and β-TCP. The HAp/45S5 (x = 60, 80 wt.%) composites after sintering included Ca5(PO4)2SiO4 and NaCaPO4. The greater amount of 45S5 was, the composites’ density and molar volume were decreased. Opposite, the hardness of composites increased as 45S5 increased and had a maximum value at 60 wt.% of 45S5. However, the hardness of all HAp/45S5 composites was lower compared with pure HAp. | No measurements were taken. | [79] | |
(100 − x)HAp/xBG_Ca (BG_Ca = 47.3 SiO2/45.6 CaO/4.6 Na2O/2.6 P2O5, mol.%); (100 − x)HAp/x45S5, x = 20, 40 wt.% | T = 800 °C (HAp/BG_Ca), T = 1150 °C (HAp/45S5), heating rate = 10 °C/min, t = 3 h | The HAp/BG_Ca composites included HAp and amorphous phase after sintering at 800 °C. There was no reaction between HAp and BG_Ca glass in it. The HAp/45S5 composites included CaSiO3 and NaCaPO4 after sintering at 1150 °C. | SBF (14 days of immersion) test showed apatite layer formation for all composites, especially for HAp/BG_Ca due to the amorphous phase presence. The MC3T3-E1 cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds, especially on HAp/BG_Ca composites. The HAp/BG_Ca with x = 40 wt.% showed a tendency to dramatically increase ALP activity in MC3T3-E1 between 2 and 7 days. | [80] | |
(100 − x)HAp/xBioK (BioK = 46.1 SiO2/26.9 CaO/24.4 K2O/2.6 P2O5, mol.%); (100 − x)HAp/x45S5, x = 50 wt.% | T = 750 °C (HAp/BioK), T = 1150 °C (HAp/45S5), heating rate = 5 °C/min, t = 3 h | The HAp/BioK composite included HAp, amorphous phase, and KCaPO4 after sintering at 750 °C. There was no reaction between HAp and BioK glass in it. The HAp/45S5 composite included HAp, Na2Ca2Si3O9, Ca3(Si3O9), and NaCaPO4 after sintering at 1150 °C. Composites had a porosity of about 30 vol%. The initial HAp/BioK microhardness (≈ 60 HV) was lower than the HAp/45S5 (≈130 HV). | SBF (14 days of immersion) test showed apatite layer formation for all composites, but higher rate formation was obtained for HAp/BioK because HAp/45S5 has wide crystallization during the sintering process. The value of HAp/BioK microhardness remained almost stable in the SBF test, and it was in the same order as that of the HAp/45S5 after 14 days of immersion. | [81] | |
(100 − x)HAp/x45S5, x = 1, 2.5, 5, 10, 25 wt.% | T = 1200 °C, heating rate = 4 °C/min, cooled rate = 10 °C/min, t = 4 h | Composites with x = 1–5 wt.% included HAp and β-TCP (conversion of HAp to β-TCP increased as the extent of 45S5 and had max (35%) at 5 wt.% of 45S5). There was no evidence of any crystalline silicate phases. These composites had closed porosity in the sintered product and higher levels of densification. Composites with x = 10 wt.% included Ca5(PO4)2SiO4, β-TCP, and amorphous phase. Composites with x = 25 wt.% included Na3Ca6(PO4, and amorphous phase. These composites had porosity (14 and 10%, respectively) and lower levels of densification. The compressive strength increased as 45S5 content increased. | Incubation in DMEM (with and without the BMSCs) for 6 days showed apatite layer formation for all composites, especially for 25 wt.% of 45S5. However, the DNA concentration was higher for composite with 10 wt.% of 45S5. The composite with 25 wt.% of 45S5 showed the highest level of ALP activity. | [82] | |
Cements | |||||
No sintering | (100 − x)(TTCP+DCPA)/x45S5, x = 0, 10, 20 wt.% | 100% relative humidity box, T = 37 °C, t = 24 h (a hardening liquid = potassium phosphate buffers) | The hardened CPC included only HAp, the CPC/45S5 with x = 10 wt.% included HAp and Ca2SiO4, and the CPC/45S5 with x = 20 wt.% included HAp, Ca2SiO4, and Ca3SiO5 after setting for 24 h in a 100% relative humidity box at 37 °C. The setting time of the cement pastes increased from 15 min to 21 and 25 min as 45S5 content increased. The injectability of pastes and compressive strength of hardened composites (after setting for 7 days) increased too. The compressive strength of the CPC/45S5 with x = 20 wt.% reached 26 MPa at 1 day and 40 MPa at 7 days compared with only 15 MPa and 22 MPa of CPC at the same time points, respectively. | SBF (14 days of immersion) test showed a homogeneous and dense apatite layer formation and a high degradation rate (which could be adjusted by controlling the 45S5 content) for 45S5-contained composites. The rat osteoblasts were able to attach, spread, and proliferate safely without toxic interference from the composites, especially on the CPC/45S5 with x = 20 wt.%. The ALP activity of cells cultured on this composite was significantly higher than that of those on the CPC. The 45S5-contained implants incorporated well with the surrounding tissue and exhibited more effective osteogenesis and osteointegration at the defect area than CPC with good biocompatibility and biodegradability in vivo (no inflammatory response, rejection, or necrosis). | [90] |
(100 − x)(TTCP+DCPA)/x45S5, x = 7.5, 15 wt.% | 100% relative humidity box, T = 37 °C, t = 10 min (a hardening liquid = monosodium phosphate solution) | All composites included TTCP, nanomonetite, and amorphous 45S5 after setting for 10 min in a 100% relative humidity box at 37 °C. All composites included calcium-deficient hydroxyapatite, remaining TTCP, and amorphous 45S5 after hardening in SBF solution at 37 °C for 3 days. The composite with 15 wt.% included the remaining origin bioglass particles. The compressive strength decreased from 44 MPa to 30 MPa after hardening in SBF solution as 45S5 content increased, while setting time increased from 4 min to 11 min. | There was a rise in cytotoxicity of composite cements as 45S5 content increased. Nevertheless, composite with 7.5 wt.% of 45S5 stimulated the population growth of cells with culture time and the differentiation of MSC to osteoblast line even in the first two days after seeding. | [91] | |
Coatings | |||||
Electrospinning | HAp/(45S5/PLGA) | t = 10, 20, 30 min (spinning time); rotated speed = 230 rpm (HAp scaffolds); pumping rate = 1 mL/h (45S5/PLGA); voltage = 13 kV | Scaffolds of HAp/(45S5/PLGA): 45S5/PLGA solution (45S5/PLGA = 1:10) was coated around the HAp scaffolds (replica method) through the electrospinning process. The greater the spinning time was, the more both the composite thickness and the amount of 45S5 increased. 45S5 was in a pure state in the composite fibers. | The MC3T3-E1 cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds. The scaffold with 30 min spinning showed a tendency to dramatically increase ALP activity and induced the protein expression of OPN in MC3T3-E1. The mineralization activity of the MC3T3-E1 was observed on day 21 for scaffolds with a greater 45S5 concentration. | [85] |
Pulsed laser deposition | (100 − x)HAp/x45S5, x = 0, 5, 10, 20, 50, and 80 wt.% | T = 600 °C (substrate temperature) [86,87], T = 200 °C (substrate temperature) [86], heating rate = 40 °C/min, t = 2 h | All PLD films included HAp and β-TCP at 600 °C. There were no peaks corresponding to 45S5. The films possessed lower amounts of P and Na elements due to P2O5 and Na2O existing in 45S5 which escaped from the plume during laser deposition. For all films obtained at 600 °C, the film adhesion strength increased as 45S5 content increased up to 20 wt.% (max adhesion). The film adhesion strength slightly decreased between 20 and 50 wt.%, and over 50 wt.% it almost did not change. The deposited film was amorphous at 200 °C and had lower adhesion strength with the substrate than the crystalline film obtained at 600 °C [86]. | The films ((100 − x)HAp/x45S5, x = 10, 20, 80 wt.% [87], and x = 50 wt.% [86]) were selected for biological safety evaluation and implantation experiment. The films did not cause a hemolytic reaction, and L929 mouse fibroblasts were able to proliferate safely without toxic interference from the films. The in vivo test indicated the implant deposited at 600 °C had higher bonding strength with the new bone tissue compared with the implant deposited at 200 °C [86]. The film with 20 wt.% of 45S5 deposited at 600 °C exhibited better osteoconduction but still not enough coupling between the implant and bone tissue under the load. | [86,87] |
CoBlast | HAp/45S5 | Pressure = 75 psi, nozzle angle = 82 and 78°, nozzle height = 8 and 16 mm, speed = 13 and 15 mm/s for HAp and 45S5 | The HAp/455 coatings were compared with 45S5 coating and commercial HAp coating (OsteoZip). The average surface roughness between 45S5 and HAp/45S5 did not differ, but OsteoZip was slightly rougher than HAp/45S5. The tendency of hydrophilicity was: 45S5 > H Ap/45S5 > OsteoZip. | The tendency of protein adsorption and MG63 cell attachment was: 45S5 > HAp/45S5 > OsteoZip. The MG63 cells were able to attach, spread, and proliferate safely without toxic interference from the coatings. The tendency of osteocalcin expression was: HAp/45S5 > OsteoZip > 45S5. The HAp/45S5 coating had the best angiogenic potential. | [88] |
Composition | Parameters of Sintering | Brief Characteristic of Materials | Evaluation of the Biocompatibility/ Bioactivity of Materials | Ref. | |
---|---|---|---|---|---|
Robocasting | (100 − x)TCP/x45S5 x = 50 wt.% | T = 1150 °C, heating rate = 5 °C/min, t = 1 h | Composite β-TCP/45S5 after sintering included Na4Ca4Si6O18, Na2CaSiO4, and NaCaPO4. The scaffolds showed high resistance to applied load with average ultimate compressive strength of 17.39 MPa and did not break at once. The scaffold had a hierarchical and repeating ordered structure with an average pore diameter of about 580 × 470 µm and a total porosity of about 40.6%. | SBF (14 days of immersion) test showed apatite layer formation for the scaffold. The hADMSCs were able to attach, spread, and proliferate safely. Scaffold had acceptable cytocompatibility. | [101] |
(100 − x)TCP/x45S5, x = 0, 5, 20, 40, 60, 80, 100 vol.% | T = 1000 °C, T = 1100 °C, heating rate = 2 °C/min, cooled rate = 4 °C/min, t = 1 h | Composites after sintering at 1100 °C with x = 5 vol.% included β-TCP and HAp; with x = 20 vol.% included β-TCP, HAp, and β-CaSiO3; with x = 40, 60 vol.% included β-CaSiO3 and NaCaPO4; with x = 80 vol.% included NaCaPO4 and Na2Ca2Si3O9; with x = 100 vol.% included Na2Ca2Si3O9. Composites after sintering at 1000–1100 °C with x = 0–40 vol.% possessed porosity (hardly any sintering between the individual particles did not occur) and low bending strength (≤20 MPa), contrasting with x = 60 (≤20 MPa at 1000 °C and ≈45 MPa at 1100 °C) and 80 vol.% (≈105 MPa). | No measurements were taken. | [102] | |
Foaming | (100 − x)TCP/x45S5 x = 20 wt.% (Vitoss BA Foam Pack) x = 0 wt.% (Vitoss Foam Pack) | - | Cylindrically shaped scaffolds were obtained (height ≈ 2.7 mm, diameter = 5 mm). The total scaffold volume was 31.86 mm3 for Vitoss and 34.58 mm3 for Vitoss BA scaffolds. | The hBMSCs were able to attach, spread, proliferate, and differentiate safely without toxic interference from the scaffolds, especially on Vitoss BA. It was established that the hBMSC differentiation and maturation were faster in Vitoss BA (higher ALP and osteogenic target genes (COL-1A, SPP-1, RUNX-2) activity) due to Vitoss BA possessing higher pH. The viability of the cells increased significantly in Vitoss BA. | [103] |
Immersion | The β-TCP scaffolds were immersed 3 times under pressure in the sol-gel solution of 45S5 (90%TCP/10%45S5). | T = 1200 °C, heating rate = 5 °C/min, t = 2 h | Composites of β-TCP/45S5 after sintering included β-TCP, α-TCP, SiO2, Na15,78Ca3(Si6O12), and CaSiO3. The density, porosity, and compressive strength of the β-TCP (0.8 g/cm3, 72.4%, 2.98 MPa) and β-TCP/45S5 (0.8 g/cm3, 72.9%, 3.29 MPa) scaffolds were similar. | SBF test showed apatite layer formation for β-TCP/45S5. The MG-63 cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds, especially on β-TCP/45S5. The ALP activity was slightly higher on the β-TCP/45S5 surface. β-TCP/45S5 inhibited the proliferation of E. coli, S. aureus, and C. albicans. | [104] |
Gel-casting | (100 − x)TCP/x45S5 x = 5, 7.5 wt.% | T = 1200 °C, heating rate = 5 °C/min, t = 2 h | Scaffolds of β-TCP/45S5 possessed bimodal porosity similar to β-TCP scaffolds (≈83–84%), but their compressive strength was twice as high (≈1.5 MPa). Composites of β-TCP/45S5 after sintering included β-TCP and Si/α-TCP. Any crystalline phase related to the Bioglass 45S5 did not occur. | The MG-63 cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds, especially on (100 − x)TCP/x45S5 with x = 7.5 wt.%. This scaffold showed higher viability of the cell. | [105] |
Binder jetting | (100 − x)TCP/x45S5 x = 5, 10 wt.% | T = 1250 °C, t = 2 h | Composites of β-TCP/45S5 after sintering included β-TCP, α-TCP, and Na2Ca2Si3O9. Among all scaffolds, the scaffolds with 5 wt.% of 45S5 possessed the highest bulk density (g/cm3) and compressive strength (MPa) but the lowest total porosity (%) for scaffolds with random (1.6 g/cm3, 26.7 MPa, 47.9%) and designed (1.4 g/cm3, 21.3 MPa, 54.1%) porosity, respectively. | SBF test showed apatite layer formation for all composites, especially those that were 45S5 contained. The MTT assay results with human osteoblast cells (hFOB) showed cells were able to attach, spread, and proliferate safely without toxic interference from the scaffolds. | [106] |
(100 − x)TCP/x45S5 x = 60 wt.% | T = 1000 °C | Composites of β-TCP/45S5 after sintering included NaCaPO4 and CaSiO3. Composites possessed a bending strength of ≈15 MPa after sintering at 1000 °C. | No measurements were taken. | [107] | |
Sintering | (100 − x)TCP/x45S5 x = 60 wt.% | T = 1000 °C, t = 5 h | Composites of β-TCP/45S5 after sintering included NaCaPO4, CaSiO3, and amorphous phase. The composite’s surface revealed a spongious bone-like morphology after treatment with each acid (aggressive level: HCl > H2SO4 > H2SO4-CrO3 ≈ HNO3). | Composites containing non-covalently immobilized rhBMP-2 on the surface exhibited significant biological activity in contrast to the composites with covalently bound protein on the surface. | [108] |
SLS | (100 − x)TCP/x45S5 x = 1, 2.5, 5, 10, 15 wt.% | T = 1100 °C, heating rate = 0.5 °C/min, cooled rate = 0.5 °C/min, t = 3 h | Composites of β-TCP/45S5 with x ≤ 5 wt.% after sintering included β-TCP and α-TCP; with x > 5 wt.% included β-CaSiO3 and NaCaPO4. The mechanical properties (fracture toughness, compressive strength, and stiffness values) increased with an increase in 45S5 from 0 to 5 wt.%, reached maximum values (1.67 MPam1/2, 21.32 MPa, and 264.32 MPa) at 5 wt.%, and then decreased with further increase in 45S5 to 15 wt.%. | SBF (14 days of immersion) test showed homogeneous apatite layer formation for composites with x ≥ 5 wt.%. The MG-63 cells were able to attach, spread, and proliferate safely without toxic interference from the composites, especially with x = 5 wt.%. | [109] |
DLP | (100 − x)BCP/x45S5 x = 20 wt.% BCP = HAp:TCP = 6:4 | T = 1200 °C, t = 2, 4, 6 h | Composites after sintering for 2 h included α-TCP, CaSiO3, and Na2CaSiO4; with exposure for 4 and 6 h included α-TCP, CaSiO3, Ca5(PO4)2SiO4, and Na2Ca3Si6O16. The greater the holding time was, the more growth and roughening of ceramic grains were observed. The best compressive strength was 1.735 MPa at the holding time of 4 h. | SBF (60 h immersion) test showed composite bioceramic with 20 wt.% 45S5 had better bioactivity than pure BCP. | [110] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kaimonov, M.R.; Safronova, T.V. Materials in the Na2O–CaO–SiO2–P2O5 System for Medical Applications. Materials 2023, 16, 5981. https://doi.org/10.3390/ma16175981
Kaimonov MR, Safronova TV. Materials in the Na2O–CaO–SiO2–P2O5 System for Medical Applications. Materials. 2023; 16(17):5981. https://doi.org/10.3390/ma16175981
Chicago/Turabian StyleKaimonov, Maksim R., and Tatiana V. Safronova. 2023. "Materials in the Na2O–CaO–SiO2–P2O5 System for Medical Applications" Materials 16, no. 17: 5981. https://doi.org/10.3390/ma16175981
APA StyleKaimonov, M. R., & Safronova, T. V. (2023). Materials in the Na2O–CaO–SiO2–P2O5 System for Medical Applications. Materials, 16(17), 5981. https://doi.org/10.3390/ma16175981